Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1623
This examiner grants 41% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19293697 | Cisplatin particles and uses thereof | Non-Final OA | CRITITECH, INC. |
| 17629252 | MULTIVALENT FIBROBLAST-TARGETED AGENTS AND METHODS OF USE | Non-Final OA | Purdue Research Foundation |
| 18550237 | KRAS INHIBITORS | Non-Final OA | Bristol-Myers Squibb Company |
| 17773992 | SELECTIVE DUAL HISTONE DEACETYLASE 6/8 (HDAC6/8) DEGRADERS AND METHODS OF USE THEREOF | Final Rejection | DANA-FARBER CANCER INSTITUTE, INC. |
| 17772384 | SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | Final Rejection | DANA-FARBER CANCER INSTITUTE, INC. |
| 17771896 | COMPOUNDS AND METHODS FOR POTENTIATING COLISTIN ACTIVITY | Final Rejection | University of Notre Dame du Lac |
| 17998275 | ATR INHIBITORS FOR THE TREATMENT OF CANCER | Non-Final OA | AstraZeneca AB |
| 18032096 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | Non-Final OA | Bayer Aktiengesellschaft |
| 18032067 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | Non-Final OA | Bayer Aktiengesellschaft |
| 18385277 | GLUTARIMIDES FOR MEDICAL TREATMENT | Final Rejection | C4 Therapeutics, Inc. |
| 18562251 | BIFUNCTIONAL PROTAC-TYPE COMPOUNDS TARGETING PXR, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | Non-Final OA | École Nationale Supérieure de Chimie de Montpellier |
| 18155587 | G9A INHIBITION DECREASES STRESS-INDUCED AND DEPENDENCE-INDUCED ESCALATION OF ALCOHOL DRINKING | Non-Final OA | MUSC Foundation for Research Development |
| 17885578 | ERBB RECEPTOR INHIBITORS | Final Rejection | Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
| 18249195 | PHARMACEUTICAL COMPOSITION BASED ON NALBUPHINE AND/OR ITS SALTS FOR NASAL ADMINISTRATION | Non-Final OA | Pharmbiotest Poland Sp. z o. o. |
| 18032098 | SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF | Non-Final OA | CarthroniX, Inc. |
| 17641257 | COMBINATION OF ZIDOVUDINE AND FLUOROQUINOLONE ANTIBIOTIC | Non-Final OA | HELPERBY THERAPEUTICS LIMITED |
| 18157224 | MTORC1 MODULATORS AND USES THEREOF | Non-Final OA | Aeovian Pharmaceuticals, Inc. |
| 17698253 | SUBSTITUTED AROMATIC FUSED RING DERIVATIVE AND COMPOSITION COMPRISING SAME, AND USE THEREOF | Non-Final OA | Shenzhen TargetRx, Inc. |
| 17915275 | PHARMACEUTICAL COMBINATION AND USE THEREOF | Final Rejection | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. |
| 17813318 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | Final Rejection | THE UNIVERSITY OF MONTANA |
| 17777103 | INHIBITORS OF HIF-2ALPHA | Non-Final OA | ARCUS BIOSCIENCES, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy